Last €49.78 EUR
Change Today +0.57 / 1.15%
Volume 100.0
JUD On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 9:32 AM 09/1/14 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (JUD) Snapshot

Open
€49.86
Previous Close
€49.21
Day High
€49.86
Day Low
€49.78
52 Week High
07/9/14 - €51.64
52 Week Low
09/4/13 - €38.12
Market Cap
14.2B
Average Volume 10 Days
43.9
EPS TTM
--
Shares Outstanding
284.7M
EX-Date
09/26/14
P/E TM
--
Dividend
€1.08
Dividend Yield
1.53%
Current Stock Chart for ST JUDE MEDICAL INC (JUD)

st jude medical inc (JUD) Related Businessweek News

View More BusinessWeek News

st jude medical inc (JUD) Details

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems that provide therapy to patients suffering from heart conditions, such as sudden cardiac arrest; and cardiac resynchronization therapy devices to treat patients suffering from heart failure. It also provides pacemakers for patients whose hearts beat too slowly or who suffer from other cardiac arrhythmias; leads to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment, which are used by physicians and healthcare professionals to program cardiac rhythm management devices and analyze device data to enhance patient management. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, vascular plugs, percutaneous catheter introducers, and diagnostic guidewires; and transcatheter aortic heart valves, heart valve repair and replacement products, and transcatheter structural heart defect devices. Further, it provides electrophysiology introducers and catheters, and ablation systems, as well as cardiac mapping, navigation, and recording systems for diagnosing and treating various irregular heart rhythms. Additionally, the company offers neurostimulation systems for chronic pain, such as rechargeable and primary cell implantable pulse generators. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in Saint Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/14
Founded in 1976

st jude medical inc (JUD) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $430.0K
Chief Operating Officer
Total Annual Compensation: $730.0K
President of International Division
Total Annual Compensation: $752.4K
Executive Vice President
Total Annual Compensation: $730.0K
Compensation as of Fiscal Year 2013.

st jude medical inc (JUD) Key Developments

St. Jude Medical, Inc. Announces Approval of Center for Medicare and Medicaid Services for New Technology Add-on Payment for the CardioMEMS HF System

St. Jude Medical Inc. announced that the Center for Medicare and Medicaid Services (CMS) has approved a New Technology Add-on Payment (NTAP) for the CardioMEMS HF System. The CardioMEMS HF System is the U.S. Food and Drug Administration approved heart failure (HF) monitoring device that has been proven to significantly reduce hospital admissions when used by physicians to manage heart failure. The NTAP program, which recognizes new technologies that provide substantial clinical improvement over already available therapies, is designed to support timely access to innovative technologies for Medicare beneficiaries. The CardioMEMS HF System allows clinicians to monitor pulmonary artery (PA) pressures in order to proactively manage medications and other treatment options while also providing an early indication of worsening HF. The CardioMEMS HF System is supported by strong clinical evidence, including data from the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Patients) trial published in The Lancet. The CHAMPION trial demonstrated a 37% reduction in HF hospitalizations during an average follow-up duration of 15 months.

St. Jude Medical Cuts 270 Jobs at California Plant

St. Jude Medical Inc. announced is laying off about 270 workers at its Sylmar, CA facility. The layoffs were effective July 28, according to the Worker Adjustment and Retraining Notification.

St. Jude Medical Inc. Declares Third Quarter Dividend, Payable October 31, 2014

St. Jude Medical Inc. announced that its board of directors declared a third quarter dividend of $0.27 per common share. This dividend amount is equal to the dividend paid during the first and second quarters of 2014 and brings the total dividend declared for the year to $0.81 per share. The dividend is payable October 31, 2014, to shareholders of record on September 30, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €49.78 EUR +0.57

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $12.68 USD +0.33
Coloplast A/S kr477.30 DKK +6.70
Smith & Nephew PLC 1,053 GBp +10.00
Terumo Corp ¥2,610 JPY -8.00
Zimmer Holdings Inc $99.31 USD -0.14
View Industry Companies
 

Industry Analysis

JUD

Industry Average

Valuation JUD Industry Range
Price/Earnings 21.2x
Price/Sales 3.3x
Price/Book 4.7x
Price/Cash Flow 20.7x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.